Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 147Breast Neoplasms 108Lung Neoplasms 92Carcinoma, Non-Small-Cell Lung 77Neoplasm Metastasis 68Glioblastoma 68Brain Neoplasms 64Glioma 59Pancreatic Neoplasms 45Carcinoma, Renal Cell 43Multiple Myeloma 41Squamous Cell Carcinoma of Head and Neck 39Colorectal Neoplasms 38Lymphoma, Large B-Cell, Diffuse 37Neoplasms 34Melanoma 32Lymphoma 32Carcinoma, Hepatocellular 32Urinary Bladder Neoplasms 31Ovarian Neoplasms 29Astrocytoma 28Sarcoma 25Oropharyngeal Neoplasms 24Lymphoma, Follicular 23Central Nervous System Neoplasms 23Rectal Neoplasms 22Uterine Cervical Neoplasms 21Triple Negative Breast Neoplasms 21Mouth Neoplasms 21Lymphoma, Non-Hodgkin 21

Interventions

telotristat ethyl 4lanreotide 2telotristat 1pasireotide 1lutetium Lu 177 dotatate 1alpha-methyltryptophan 1Receptor-Like Protein Tyrosine Phosphatases, Class 2 1Random Allocation 1Panitumumab 1Octreotide 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Serotonin Syndrome × Magnetic Resonance Spectroscopy × Clear all
NCT03453489 2025-04-10

AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
4 enrolled 7 charts

Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡